What is it about?
PCSK-9 inhibitors are new drugs that help lower cholesterol for people with very sever problems. This paper describes how well the new drug works in the first patients initiated on the treatment in a DGH lipid clinic and a teaching hospital lipid clinic
Featured Image
Why is it important?
It proves that in the real world, results of treatment are as good as they are in clinical trials of carefully selected patients
Perspectives
PCSK-9 inhibitors are very expensive so must be used with care in a selected group of patients who can benefit most. The paper shows that they work well in their target population.
Tim Reynolds
Queen's Hospital, Burton on Trent
Read the Original
This page is a summary of: Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres, International Journal of Clinical Practice, October 2017, Wiley,
DOI: 10.1111/ijcp.13032.
You can read the full text:
Contributors
The following have contributed to this page
